Navigation Links
3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Date:11/10/2012

th IC50s in the 5-50nM range;
  • Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN;
  • Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and
  • Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors.
  • 3-V's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties.  The company has filed multiple worldwide patent applications covering these inhibitors.  3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

    Data describing 3-V's FASN inhibitor preclinical activity will be presented by Dr. Kemble during Sunday's HCV Therapy: Preclinical and Early Clinical Development parallel session at 5:30 pm in a talk titled: "Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase" (Abstract #88).  A poster, "TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition in Vivo" (Abstract #1876), describing mechanism and activity for one of 3-V's compounds will be presented on Tuesday, November 13 during the HCV Therapy: Preclinical and Early Clinical Development poster session from 8:00 a.m. to 12:00 p.m.

    About FASN
    FASN is a cellular enzyme implicated in HCV replication and several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and ha
    '/>"/>

    SOURCE 3-V Biosciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
    2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
    3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
    4. Neurocrine Biosciences Reports First Quarter 2012 Results
    5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
    6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
    8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
    9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
    10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
    11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... 2014 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or ... quality medical marijuana products, is pleased to announce that ... signed a definitive lease agreement for a second facility ... facility has 28,966 square feet of floor space with ... mezzanine space for a total of approximately 43,500 square ...
    (Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
    (Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
    Breaking Medicine Technology:T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
    (Date:9/22/2014)... 22, 2014 (HealthDay News) -- New research raises doubts ... cancer. Smokers with cancer who used e-cigarettes along ... those who didn,t use the devices, a Memorial Sloan ... likely -- or less likely -- to have quit ... The study, published online Sept. 22 in Cancer ...
    (Date:9/22/2014)... Montreal, Quebec (PRWEB) September 22, 2014 ... understanding of chronic myelogenous leukemia, a form of blood ... CML is caused by a mutation affecting chromosomes 22 ... become a powerful symbol as the worldwide community unites ... it affects. , CML is at the forefront of ...
    (Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 ... City, has just posted a new article to its ... feel more than just a tad dismayed. Titled “Coffee ... article, http://www.lifeant.com/coffee-drinkers-beware-paying-life-insurance/ states on average, coffee fans ... premiums than those who do not enjoy the tasty ...
    (Date:9/22/2014)... (PRWEB) September 22, 2014 As football season ... starting to put together their fantasy football leagues to prep ... also prepping as they work on new ways to bring ... Mica Lounge, located in the Sheraton Silver Spring Hotel, is ... own “Sheraton League” where locals and hotel guests can sign ...
    (Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... - Dr. Beth Schrope , NewYork-Presbyterian/Columbia University ... or auto islet surgery, to prevent diabetes in ... is the first center in the New York ... Every year, roughly 87,000 people in the United ...
    Breaking Medicine News(10 mins):Health News:E-Cigarettes Don't Help Cancer Patients Quit Smoking: Study 2Health News:Marking World CML Day on September 22nd 2Health News:Marking World CML Day on September 22nd 3Health News:Coffee Drinkers Are Charged More For Life Insurance, Reports LifeAnt.com 2Health News:Sheraton Silver Spring Hotel Keeps Football Fans Engaged Online and in their Lounge 2Health News:Sheraton Silver Spring Hotel Keeps Football Fans Engaged Online and in their Lounge 3Health News:Sheraton Silver Spring Hotel Keeps Football Fans Engaged Online and in their Lounge 4Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 2Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 3
    ... A new study investigating the potential beneficial effects ... of anti-TNFa treatment in aging," appears in the ... ,This study shows hope for significantly ... been linked to blood vessel dysfunction and cell ...
    ... to your high blood pressure might just be your ... evidence suggests that inflammation, a part of the immune ... diabetes, may also help translate stress into high blood ... is an inflammatory condition,” says Dr. Haidong Zhu, molecular ...
    ... reduction pill, which works better and faster than existing drugs// ... and cancer. ,Existing anti-obesity pills generally cut weight ... ,But men and women taking Excalia, the new ... lost 12 percent of their body weight, according to the ...
    ... undergo a double hand transplant was ecstatic as she got ... "I'm doing very well, I'm very happy. I'm taking steps ... life. When I saw the hands after the operation, they ... her arms following an explosion in a laboratory in 1978, ...
    ... better safety for patients in ICU by adhering to ... threatening// catheter-related infections. ICUs can become thoroughly aseptic by ... syringes and catheters. A detailed report was made by ... of the report are published in New England Journal ...
    ... more people succumbed to Rift Valley Fever in Garissa district, ... has been made by the North Eastern Provincial// Medical Officer ... cautioned the public to seek medical attention as quickly as ... the disease is due to lack of awareness. But local ...
    Cached Medicine News:Health News:Effects Of Age-related Vascular Diseases Can Be Reduced By Inactivating TNFa 2Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 2Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 3Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2
    Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
    Skin Tone External Eyelid Weights...
    To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
    Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
    Medicine Products: